Second malignancies after breast cancer: The impact of different treatment modalities

British Journal of Cancer

Volumn 98, Issue 5, 2008, Pages 870-874

  Kirova, Y M ^a   De Rycke, Y ^a   Gambotti, L ^a   Pierga, J Y ^a   Asselain, B ^a   Fourquet, A ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast cancer; Chemotherapy; Hormone therapy; Longterm risk; Radiotherapy; Second malignancies; Second malignant neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; COBALT 60; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; DIGESTIVE SYSTEM CANCER; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; FRANCE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; LEUKEMIA; LINEAR ACCELERATOR; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; SARCOMA; SECOND CANCER; THYROID CANCER; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER;

BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 40349098159     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604241     Document Type: Article

References (49)

1. Ahsan H, Neugut AI (1998) Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Int Med 128: 114-117
2. Blamey RW, Mackay J, Macmillan D (2004) EUSOMA guidelines on the management of familial breast cancer risk. Eur J Cancer 2: 155 (abstract)
3. Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349: 1505-1510
4. Brenner H, Siegle S, Stegmaier C, Ziegler H (1993) Second primary neoplasms following breast cancer in Saarland, Germany, 1968-1987. Eur J Cancer 29: 1410-1414
5. Campana F, Kirova YM, Rosenwald JC, Dendale R, Vilcoq JR, Dreyfus H, Fourquet A (2005) Breast radiotherapy in the lateral decubitus position - a technique to prevent lung and heart irradiation. Int J Radiat Oncol Biol Phys 61: 1348-1354
6. Chappuis PO, Nethercot V, Foulkes WD (2000) Clinico-pathological characteristics of BRCA1 and BRCA2-related breast cancer. Semin Surg Oncol 8: 287-295
7. Deutsch M, Land SR, Begovic M, Wieand HS, Wolmark N, Fisher B (2003) The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of NSABP clinical trials B-04 and B-06. Cancer 98: 1362-1368
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 366: 2087-2106
9. Easton DF, Bishop DT, Ford D, Crockford GP (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52: 678-701
10. Ewertz M, Mouridsen H (1985) Second cancer following cancer of the female breast in Denmark, 1943-80. Natl Cancer Inst Monogr 68: 325-329
11. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90: 1371-1388
12. Fourquet A, Campana F, Rosenwald JC, Vilcoq JR (1991) Breast irradiation in the lateral decubitus position: technique of the Institut Curie. Radiother Oncol 22: 261-265
13. Fox MS (1979) On the diagnosis and treatment of breast cancer. JAMA 241: 489-494
14. Galper S, Gelman R, Recht A, Silver B, Kohli A, Wong JS, Van Buren T, Baldini EH, Harris JR (2002) Second non breast malignancies after conservative surgery and radiation therapy for early stage breast cancer. Int J Radiat Oncol Biol Phys 52: 406-414
15. Haber D (2002) Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 346: 1660-1662
16. Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/BRCA2 status. Lancet 359: 1471-1477
17. Inskip PD, Stoval M, Flannery JT (1994) Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 86: 983-988
18. Jones VE, Raghavan D (1993) Quantum leaps in treatment of high-risk breast cancer? Prove it!. Eur J Cancer 10: 1488-1493
19. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
20. Karlsson P, Holmberg E, Samuelsson A, Johansson KA, Wallgren A (1998) Soft tissue sarcoma after treatment for breast cancer - a Swedish population-based study. Eur J Cancer 34: 2068-2075
21. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K (2002) Risk reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609-1615
22. Kirova Y, Savignoni A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fourquet A (2006a) Risk of second non breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving treatment. Eur J Cancer 4: 127-128 (abst 276)
23. Kirova Y, Servois V, Campana F, Dendale R, Bollet MA, Laki F, Fourquet A (2006b) CT-scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning. Radiother Oncol 79: 310-315
24. Kirova YM, Feuilhade F, Calitchi E, Otmezguine Y, Le Bourgeois JP (1998) Radiation-induced sarcomas following radiotherapy for breast cancer: six case reports and a review of the literature. Breast 7: 277-282
25. Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A (2007) Risk of second malignancies (SM) following adjuvant radiotherapy (RT) for breast cancer (BC): a large scale single institution review. Int J Radiat Oncol Biol Phys 68: 359-363
26. Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A, for the Institut Curie Breast Cancer Study Group (2005a) Risk of second non breast malignancies (SNBM) in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 41: 2304-2311
27. Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet A (2005b) Radiation-induced sarcomas (RIS) following radiotherapy for breast cancer: a large-scale single institution review. Cancer 104: 856-863
28. Klijn JG, Janin N, Cortés-Funes H, Colomer R (1997) Should prophylactic surgery be used in women at high risk of breast cancer? Eur J Cancer 33: 2149-2159
29. Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X, Stoppa-Lyonnet D, Salmon R (2007) Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer 109: 1784-1790
30. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, Dukel L, Devilee P, van den Ouweland AM, van Geel AN, Klijn JG (2000) Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355: 2015-2020
31. Mellemkjaer L, Friis S, Olsen JH, Scélo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-Seng C, Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan P (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118: 2285-2292
32. Neugut AI, Robinson E, Lee WC, Murray T, Karwoski K, Kutcher GJ (1993) Lung cancer after radiation therapy for breast cancer. Cancer 71: 3054-3057
33. Obedian E, Fischer DB, Haffty BG (2000) Second malignancies after treatment of early stage breast cancer. Lumpectomy and radiation therapy vs mastectomy. J Clin Oncol 18: 2406-2412
34. Pierce L, Levin A, Rebbeck T (2003) Ten-year outcome of breast-conserving surgery and radiotherapy in women with breast cancer and germline BRCA1/2 mutations: results from an international collaboration. Breast Cancer Res Treat 82: S7 (#5), (abstr)
35. Pierce L (2002) Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas. Semin Radiat Oncol 12: 352-361
36. Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, Gaffney D, Solin LJ, Nixon A, Garber J, Berg C, Isaacs C, Heimann R, Olopade OI, Haffty B, Weber BL (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18: 3360-3369
37. Remontet L, Buemi A, Velten M, Jougla E, Estève J (2003) Evolution de l'incidence et de la mortalité par cancer en France de 1978 à 2000 Robson ME (2002) Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. Cancer Control 9: 457-465
38. Rubino C, de Vathaire F, Diallo I, Shamsaldin A, G Lê M (2000) Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 61: 183-195
39. Salmon RJ, Asselain B, Le Gal M (1997) Twelve years experience of breast cancer at the Institut Curie: improvement of survival and value of screening mammographics. Breast 6: 202-205
40. Scholl B, Reis ED, Zouhair A, Chereshnev I, Givel JC, Gillet M (2001) Esophageal cancer as second primary tumor after breast cancer radiotherapy. Am J Surg 182: 476-480
41. Schrag D, Kuntz KM, Garber JE, Weeks JC (1997) Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336: 1465-1471
42. Seynaeve C, Verhoog LC, van de Bosch LM, van Geel AN, Menke-Pluymers M, Meijers-Heijboer EJ, van den Ouweland AM, Wagner A, Creutzberg CL, Niermeijer MF, Klijn JG, Brekelmans CT (2004) Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40: 1150-1158
43. Shousha S, Fawcett A, Luqmani YA, Theodorou N (2001) Multifocal squamous cell carcinoma of the oesophagus following radiotherapy for bilateral breast carcinoma. J Clin Pathol 54: 718-720
44. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, Clough KB, Magdelénat H, Pouillart P, Vincent-Salomon A, Fourquet A, Asselain B (2000) Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 18: 4053-4059
45. Turner BC, Harrold E, Matloff E, Smith T, Gumbs AA, Beinfield M, Ward B, Skolnick M, Glazer PM, Thomas A, Haffty BG (1999) BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 17: 3017-3024
46. Volk N, Pompe-Kirn V (1997) Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 8: 764-770
47. Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK, Hamre M (2002) Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 52: 1231-1237
48. Zablotska LB, Chak A, Das A, Neugut AI (2005) Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am J Epidemiol 161: 330-337
49. Zablotska LB, Neugut AI (2003) Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 97: 1404-1411